AstraZeneca Korea has initiated an early retirement program following the withdrawal of the diabetes treatment Forxiga from the Korean market. The company has stated that it is in discussions with the government to minimize the impact of Forxiga’s withdrawal along with its business unit restructuring.

According to the pharmaceutical industry sources on the 18th, AstraZeneca Korea is currently implementing an Early Retirement Plan (ERP). Under this plan, the ERP compensation package is structured as of January 2024, with a monthly base salary*(years of service*2+8) + 130 million won. For example, an employee earning a monthly base salary of 5 million won with 10 years of service would receive an additiona